Generic Medicine

sofosbuvir and daclatasvir

About sofosbuvir and daclatasvir

Daclatasvir and sofosbuvir are two direct-acting antiviral (DAA) medications that are commonly used in combination to treat chronic hepatitis C virus (HCV) infection. Daclatasvir is an NS5A inhibitor, while sofosbuvir is a nucleotide analog that inhibits the HCV NS5B RNA polymerase. Together, these two medications are highly effective against all six major HCV genotypes and have a very high safety profile.

The combination of daclatasvir and sofosbuvir is typically prescribed for 12 weeks, but the duration of treatment may vary depending on the patient's individual characteristics, such as the HCV genotype, liver function, and treatment history. This combination therapy is very well-tolerated, with the most common side effects being fatigue, headache, and nausea.

Daclatasvir and sofosbuvir are highly effective in achieving sustained virological response (SVR), which is defined as undetectable HCV RNA levels at 12 weeks after the completion of treatment. SVR is considered to be a cure for HCV infection. In clinical trials, the SVR rate for daclatasvir and sofosbuvir combination therapy was over 95% for all major HCV genotypes, including in patients with cirrhosis and other difficult-to-treat populations.

The combination of daclatasvir and sofosbuvir is now the standard of care for the treatment of chronic HCV infection. It is a safe and effective treatment for all major HCV genotypes, regardless of treatment history or liver function.